A Covid-19 threat to business acquisitions
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
Few groups have developed Covid-19 diagnostics – but this will change
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
Thermo Fisher buys Qiagen after all
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Veracyte’s nasal lung cancer test results raise questions
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
Who will buy Qiagen?
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
